A phase 1/2, open-label, multicenter study to investigate the safety, pharmacokinetics, and efficacy of fadraciclib (CYC065), an oral CDK2/9 inhibitor, in subjects with advanced solid tumors and lymphoma

S. Piha-Paul; D. Y. Oh; E. Garralda; M. Vieito; J. Huang; M. Kirschbaum; M. Villanona-Calero

doi:10.1016/S0959-8049(22)00849-8

A phase 1/2, open-label, multicenter study to investigate the safety, pharmacokinetics, and efficacy of fadraciclib (CYC065), an oral CDK2/9 inhibitor, in subjects with advanced solid tumors and lymphoma

S. Piha-Paul, D. Y. Oh, E. Garralda, M. Vieito, J. Huang, M. Kirschbaum, M. Villanona-Calero

Investigational Cancer Therapeutics

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	S17-S18
Journal	European Journal of Cancer
Volume	174
DOIs	https://doi.org/10.1016/S0959-8049(22)00849-8
State	Published - Oct 2022

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/S0959-8049(22)00849-8

Cite this

Piha-Paul, S., Oh, D. Y., Garralda, E., Vieito, M., Huang, J., Kirschbaum, M., & Villanona-Calero, M. (2022). A phase 1/2, open-label, multicenter study to investigate the safety, pharmacokinetics, and efficacy of fadraciclib (CYC065), an oral CDK2/9 inhibitor, in subjects with advanced solid tumors and lymphoma. European Journal of Cancer, 174, S17-S18. https://doi.org/10.1016/S0959-8049(22)00849-8

A phase 1/2, open-label, multicenter study to investigate the safety, pharmacokinetics, and efficacy of fadraciclib (CYC065), an oral CDK2/9 inhibitor, in subjects with advanced solid tumors and lymphoma. / Piha-Paul, S.; Oh, D. Y.; Garralda, E. et al.
In: European Journal of Cancer, Vol. 174, 10.2022, p. S17-S18.

Research output: Contribution to journal › Article › peer-review

Piha-Paul, S, Oh, DY, Garralda, E, Vieito, M, Huang, J, Kirschbaum, M & Villanona-Calero, M 2022, 'A phase 1/2, open-label, multicenter study to investigate the safety, pharmacokinetics, and efficacy of fadraciclib (CYC065), an oral CDK2/9 inhibitor, in subjects with advanced solid tumors and lymphoma', European Journal of Cancer, vol. 174, pp. S17-S18. https://doi.org/10.1016/S0959-8049(22)00849-8

@article{f3b950b8681c46fbbfabeae2f64d3061,

title = "A phase 1/2, open-label, multicenter study to investigate the safety, pharmacokinetics, and efficacy of fadraciclib (CYC065), an oral CDK2/9 inhibitor, in subjects with advanced solid tumors and lymphoma",

author = "S. Piha-Paul and Oh, {D. Y.} and E. Garralda and M. Vieito and J. Huang and M. Kirschbaum and M. Villanona-Calero",

year = "2022",

month = oct,

doi = "10.1016/S0959-8049(22)00849-8",

language = "English (US)",

volume = "174",

pages = "S17--S18",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - A phase 1/2, open-label, multicenter study to investigate the safety, pharmacokinetics, and efficacy of fadraciclib (CYC065), an oral CDK2/9 inhibitor, in subjects with advanced solid tumors and lymphoma

AU - Piha-Paul, S.

AU - Oh, D. Y.

AU - Garralda, E.

AU - Vieito, M.

AU - Huang, J.

AU - Kirschbaum, M.

AU - Villanona-Calero, M.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85140491707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140491707&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(22)00849-8

DO - 10.1016/S0959-8049(22)00849-8

M3 - Article

AN - SCOPUS:85140491707

SN - 0959-8049

VL - 174

SP - S17-S18

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

A phase 1/2, open-label, multicenter study to investigate the safety, pharmacokinetics, and efficacy of fadraciclib (CYC065), an oral CDK2/9 inhibitor, in subjects with advanced solid tumors and lymphoma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this